import { Lead } from '@/types/lead';

export const mockLeads: Lead[] = [
  {
    id: '1',
    name: 'Dr. Sarah Chen',
    title: 'Director of Preclinical Toxicology',
    company: 'Novartis Institutes for BioMedical Research',
    email: 'sarah.chen@novartis.com',
    personLocation: 'Cambridge, MA',
    companyHQ: 'Basel, Switzerland',
    fundingStage: 'IPO',
    recentPublications: 8,
    publicationTopics: ['Drug-Induced Liver Injury', 'Hepatic Spheroids', '3D Cell Culture'],
    lastPublicationDate: '2024-11-15',
    usesInVitroModels: true,
    openToNAMs: true,
    currentTechStack: ['HepaRG Spheroids', 'Primary Hepatocyte Cultures', 'LiverChip'],
    totalScore: 94,
    roleScore: 28,
    scientificScore: 38,
    companyScore: 18,
    locationScore: 10,
    topReasons: [
      '8 recent publications on hepatotoxicity and 3D models',
      'Decision-maker role in preclinical safety',
      'Already using spheroid technologies - high adoption readiness'
    ],
    recommendedAction: 'Conference Meet',
    actionRationale: 'Presenting at SOT 2025 - ideal for in-person demo discussion',
    linkedinUrl: 'https://linkedin.com/in/sarahchen',
    conferenceAppearances: ['SOT 2024', 'AACR 2024', 'ISSX 2023'],
    researchKeywords: ['DILI', 'hepatotoxicity', 'microphysiological systems']
  },
  {
    id: '2',
    name: 'Dr. Marcus Weber',
    title: 'Head of Safety Assessment',
    company: 'BioMarin Pharmaceutical',
    email: 'marcus.weber@biomarin.com',
    personLocation: 'San Rafael, CA',
    companyHQ: 'San Rafael, CA',
    fundingStage: 'IPO',
    recentPublications: 5,
    publicationTopics: ['Rare Disease Toxicology', 'Organ-on-Chip', 'Predictive Toxicology'],
    lastPublicationDate: '2024-09-20',
    usesInVitroModels: true,
    openToNAMs: true,
    currentTechStack: ['Emulate Organ-Chips', 'iPSC-derived hepatocytes'],
    totalScore: 89,
    roleScore: 30,
    scientificScore: 35,
    companyScore: 16,
    locationScore: 8,
    topReasons: [
      'C-suite adjacent with budget authority',
      'Published on organ-chip adoption challenges',
      'Company actively investing in NAM infrastructure'
    ],
    recommendedAction: 'Direct Call',
    actionRationale: 'Recently posted about seeking new toxicology solutions',
    linkedinUrl: 'https://linkedin.com/in/marcusweber',
    conferenceAppearances: ['SOT 2024', 'ISSX 2024'],
    researchKeywords: ['organ-on-chip', 'rare disease', 'safety pharmacology']
  },
  {
    id: '3',
    name: 'Dr. Emily Rodriguez',
    title: 'VP of Preclinical Development',
    company: 'Forma Therapeutics',
    email: 'emily.rodriguez@formatherapeutics.com',
    personLocation: 'Watertown, MA',
    companyHQ: 'Watertown, MA',
    fundingStage: 'Series C+',
    recentPublications: 3,
    publicationTopics: ['Protein Degradation', 'Hepatic Safety'],
    lastPublicationDate: '2024-06-10',
    usesInVitroModels: false,
    openToNAMs: true,
    currentTechStack: ['Traditional 2D cultures', 'Animal models'],
    totalScore: 86,
    roleScore: 30,
    scientificScore: 28,
    companyScore: 18,
    locationScore: 10,
    topReasons: [
      'VP-level decision maker at growth-stage company',
      'Currently using 2D models - prime upgrade candidate',
      'Located in Boston biotech hub'
    ],
    recommendedAction: 'Email Intro',
    actionRationale: 'No existing 3D capability - education-first approach',
    linkedinUrl: 'https://linkedin.com/in/emilyrodriguez',
    conferenceAppearances: ['AACR 2024'],
    researchKeywords: ['protein degradation', 'PROTAC', 'hepatotoxicity']
  },
  {
    id: '4',
    name: 'Dr. James Liu',
    title: 'Senior Director, Drug Safety Sciences',
    company: 'Genentech',
    email: 'james.liu@gene.com',
    personLocation: 'South San Francisco, CA',
    companyHQ: 'South San Francisco, CA',
    fundingStage: 'IPO',
    recentPublications: 12,
    publicationTopics: ['Antibody Toxicology', 'Liver Models', 'ADME'],
    lastPublicationDate: '2024-12-01',
    usesInVitroModels: true,
    openToNAMs: true,
    currentTechStack: ['InSphero 3D cultures', 'Liver-on-chip', 'Organoids'],
    totalScore: 82,
    roleScore: 26,
    scientificScore: 36,
    companyScore: 12,
    locationScore: 8,
    topReasons: [
      'Prolific researcher with 12 recent publications',
      'Already using competitor products - switch potential',
      'Influential thought leader in the space'
    ],
    recommendedAction: 'Conference Meet',
    actionRationale: 'Key speaker at upcoming SOT - networking opportunity',
    linkedinUrl: 'https://linkedin.com/in/jamesliu',
    conferenceAppearances: ['SOT 2024', 'SOT 2023', 'AACR 2024', 'ISSX 2024'],
    researchKeywords: ['biologics', 'immunotoxicity', '3D liver models']
  },
  {
    id: '5',
    name: 'Dr. Anna Bergstr√∂m',
    title: 'Associate Director, DMPK',
    company: 'AstraZeneca',
    email: 'anna.bergstrom@astrazeneca.com',
    personLocation: 'Cambridge, UK',
    companyHQ: 'Cambridge, UK',
    fundingStage: 'IPO',
    recentPublications: 6,
    publicationTopics: ['Drug Metabolism', 'CYP Induction', 'Hepatocyte Models'],
    lastPublicationDate: '2024-10-05',
    usesInVitroModels: true,
    openToNAMs: false,
    currentTechStack: ['Cryopreserved hepatocytes', 'Microsomes'],
    totalScore: 78,
    roleScore: 22,
    scientificScore: 32,
    companyScore: 14,
    locationScore: 10,
    topReasons: [
      'Strong publication record in relevant domain',
      'UK Golden Triangle location',
      'DMPK focus with hepatic emphasis'
    ],
    recommendedAction: 'Warm LinkedIn Outreach',
    actionRationale: 'Connected to 3 mutual contacts in our network',
    linkedinUrl: 'https://linkedin.com/in/annabergstrom',
    conferenceAppearances: ['ISSX 2024', 'DMDG 2024'],
    researchKeywords: ['CYP enzymes', 'drug metabolism', 'hepatocytes']
  },
  {
    id: '6',
    name: 'Dr. Michael Thompson',
    title: 'Director of Translational Sciences',
    company: 'Karuna Therapeutics',
    email: 'michael.thompson@karunatx.com',
    personLocation: 'Boston, MA',
    companyHQ: 'Boston, MA',
    fundingStage: 'Series C+',
    recentPublications: 4,
    publicationTopics: ['CNS Drug Development', 'Safety Biomarkers'],
    lastPublicationDate: '2024-07-22',
    usesInVitroModels: false,
    openToNAMs: true,
    currentTechStack: ['Standard in-vitro assays', 'In-vivo models'],
    totalScore: 75,
    roleScore: 26,
    scientificScore: 24,
    companyScore: 17,
    locationScore: 8,
    topReasons: [
      'Growth-stage company with active pipeline',
      'Director-level with procurement influence',
      'Open to NAMs but not yet adopted'
    ],
    recommendedAction: 'Email Intro',
    actionRationale: 'Recently expressed interest in reducing animal testing',
    conferenceAppearances: ['SfN 2024'],
    researchKeywords: ['CNS', 'schizophrenia', 'muscarinic']
  },
  {
    id: '7',
    name: 'Dr. Yuki Tanaka',
    title: 'Principal Scientist, Toxicology',
    company: 'Takeda Pharmaceutical',
    email: 'yuki.tanaka@takeda.com',
    personLocation: 'Cambridge, MA',
    companyHQ: 'Tokyo, Japan',
    fundingStage: 'IPO',
    recentPublications: 7,
    publicationTopics: ['Hepatotoxicity Screening', 'High-throughput Tox'],
    lastPublicationDate: '2024-08-30',
    usesInVitroModels: true,
    openToNAMs: true,
    currentTechStack: ['2D hepatocyte screens', 'HepG2 cells'],
    totalScore: 72,
    roleScore: 18,
    scientificScore: 34,
    companyScore: 12,
    locationScore: 8,
    topReasons: [
      'High publication output in hepatotoxicity',
      'Using basic 2D methods - upgrade opportunity',
      'Based in Cambridge hub'
    ],
    recommendedAction: 'Conference Meet',
    actionRationale: 'Poster presenter at SOT - approachable setting',
    conferenceAppearances: ['SOT 2024', 'JSOT 2024'],
    researchKeywords: ['high-throughput screening', 'hepatotoxicity', 'HepG2']
  },
  {
    id: '8',
    name: 'Dr. Claire Dubois',
    title: 'Head of In Vitro Pharmacology',
    company: 'Servier',
    email: 'claire.dubois@servier.com',
    personLocation: 'Paris, France',
    companyHQ: 'Suresnes, France',
    fundingStage: 'Bootstrapped',
    recentPublications: 5,
    publicationTopics: ['Cardiotoxicity', 'Multi-organ Models'],
    lastPublicationDate: '2024-05-15',
    usesInVitroModels: true,
    openToNAMs: true,
    currentTechStack: ['iPSC cardiomyocytes', 'HepaRG'],
    totalScore: 68,
    roleScore: 24,
    scientificScore: 28,
    companyScore: 10,
    locationScore: 6,
    topReasons: [
      'Head of in-vitro with direct technology decisions',
      'Already using advanced cell models',
      'Focus on multi-organ systems'
    ],
    recommendedAction: 'Partner Intro',
    actionRationale: 'Connected via our French distributor network',
    conferenceAppearances: ['ESTIV 2024'],
    researchKeywords: ['cardiomyocytes', 'iPSC', 'multi-organ']
  },
  {
    id: '9',
    name: 'Dr. Robert Kim',
    title: 'Associate Director, Hepatic Biology',
    company: 'Alnylam Pharmaceuticals',
    email: 'robert.kim@alnylam.com',
    personLocation: 'Cambridge, MA',
    companyHQ: 'Cambridge, MA',
    fundingStage: 'IPO',
    recentPublications: 9,
    publicationTopics: ['RNAi Delivery', 'Liver Targeting', 'Hepatocyte Models'],
    lastPublicationDate: '2024-11-28',
    usesInVitroModels: true,
    openToNAMs: true,
    currentTechStack: ['Primary hepatocytes', 'iPSC-hepatocytes'],
    totalScore: 91,
    roleScore: 22,
    scientificScore: 39,
    companyScore: 20,
    locationScore: 10,
    topReasons: [
      'Liver-focused company with deep hepatocyte expertise',
      '9 recent publications on liver models',
      'RNAi modality requires advanced liver models'
    ],
    recommendedAction: 'Direct Call',
    actionRationale: 'High strategic fit - liver is core to their platform',
    linkedinUrl: 'https://linkedin.com/in/robertkim',
    conferenceAppearances: ['OTS 2024', 'ASGCT 2024'],
    researchKeywords: ['RNAi', 'siRNA', 'liver delivery', 'hepatocytes']
  },
  {
    id: '10',
    name: 'Dr. Sofia Andersson',
    title: 'Senior Scientist, Safety Assessment',
    company: 'Moderna',
    email: 'sofia.andersson@modernatx.com',
    personLocation: 'Cambridge, MA',
    companyHQ: 'Cambridge, MA',
    fundingStage: 'IPO',
    recentPublications: 3,
    publicationTopics: ['mRNA Safety', 'Lipid Nanoparticle Toxicity'],
    lastPublicationDate: '2024-04-10',
    usesInVitroModels: false,
    openToNAMs: true,
    currentTechStack: ['Standard toxicology assays'],
    totalScore: 64,
    roleScore: 16,
    scientificScore: 22,
    companyScore: 18,
    locationScore: 8,
    topReasons: [
      'High-growth company with expanding safety needs',
      'mRNA platform may benefit from advanced liver models',
      'Cambridge location for easy engagement'
    ],
    recommendedAction: 'Email Intro',
    actionRationale: 'Entry-level engagement to understand their roadmap',
    conferenceAppearances: ['SOT 2024'],
    researchKeywords: ['mRNA', 'LNP', 'immunogenicity']
  },
  {
    id: '11',
    name: 'Dr. David Martinez',
    title: 'VP Safety Sciences',
    company: 'Vertex Pharmaceuticals',
    email: 'david.martinez@vrtx.com',
    personLocation: 'Boston, MA',
    companyHQ: 'Boston, MA',
    fundingStage: 'IPO',
    recentPublications: 2,
    publicationTopics: ['Cystic Fibrosis', 'Drug Safety'],
    lastPublicationDate: '2024-03-05',
    usesInVitroModels: true,
    openToNAMs: true,
    currentTechStack: ['Organoids', 'Patient-derived cells'],
    totalScore: 85,
    roleScore: 30,
    scientificScore: 20,
    companyScore: 25,
    locationScore: 10,
    topReasons: [
      'VP-level with significant budget authority',
      'Vertex known for innovation adoption',
      'Already using organoid technology'
    ],
    recommendedAction: 'Direct Call',
    actionRationale: 'Connected via board member introduction',
    linkedinUrl: 'https://linkedin.com/in/davidmartinez',
    conferenceAppearances: ['NACFC 2024'],
    researchKeywords: ['cystic fibrosis', 'organoids', 'CFTR']
  },
  {
    id: '12',
    name: 'Dr. Helen Park',
    title: 'Director, Investigative Toxicology',
    company: 'Regeneron Pharmaceuticals',
    email: 'helen.park@regeneron.com',
    personLocation: 'Tarrytown, NY',
    companyHQ: 'Tarrytown, NY',
    fundingStage: 'IPO',
    recentPublications: 6,
    publicationTopics: ['Antibody Safety', 'Liver Toxicity', 'Immunogenicity'],
    lastPublicationDate: '2024-09-12',
    usesInVitroModels: true,
    openToNAMs: true,
    currentTechStack: ['3D liver spheroids', 'Primary cells'],
    totalScore: 79,
    roleScore: 26,
    scientificScore: 30,
    companyScore: 16,
    locationScore: 7,
    topReasons: [
      'Investigative tox role - evaluates new technologies',
      'Active publisher with hepatic focus',
      'Already using 3D models - expansion candidate'
    ],
    recommendedAction: 'Conference Meet',
    actionRationale: 'Confirmed attendance at SOT roundtable',
    conferenceAppearances: ['SOT 2024', 'AACR 2024'],
    researchKeywords: ['biologics', 'liver spheroids', 'off-target effects']
  }
];

export const jobTitleOptions = [
  'Director of Toxicology',
  'Head of Preclinical Safety',
  'VP Safety Assessment',
  'Director of Preclinical Development',
  'Senior Director, Drug Safety',
  'Head of In Vitro Pharmacology',
  'Principal Scientist, Toxicology',
  'Associate Director, DMPK'
];

export const keywordOptions = [
  'Drug-Induced Liver Injury',
  'Organ-on-Chip',
  'Hepatic Spheroids',
  'Microphysiological Systems',
  '3D Cell Culture',
  'NAMs',
  'ADME',
  'Hepatotoxicity'
];

export const regionOptions = [
  'Boston/Cambridge',
  'Bay Area',
  'Basel',
  'UK Golden Triangle',
  'New York Metro',
  'San Diego',
  'Paris/France',
  'Tokyo/Japan'
];

export const fundingStageOptions = [
  'Bootstrapped',
  'Seed',
  'Series A',
  'Series B',
  'Series C+',
  'IPO'
];
